(SCH-351448)-药物靶点：LDLR_专利_临床

概要

基本信息

药物类型

未知

别名

SCH 351448

靶点

LDLR(低密度脂蛋白受体)

作用机制

LDLR激动剂(低密度脂蛋白受体激动剂)

治疗领域

内分泌与代谢疾病

在研适应症-

非在研适应症

高脂血症

原研机构

Schering-Plough Corp.

在研机构-

非在研机构

Schering-Plough Corp.

最高研发状态(全球)无进展临床前

首次获批日期(全球)-

最高研发状态(中国)-

特殊审评-

关联

100 项与 SCH-351448 相关的专利（医药）

登录后查看更多信息

13

项与 SCH-351448 相关的文献（医药）

2016-07-06·Journal of the American Chemical Society1区 · 化学

Total Synthesis of (+)-SCH 351448: Efficiency via Chemoselectivity and Redox-Economy Powered by Metal Catalysis

1区 · 化学

Article

作者: Wang, Gang ; Krische, Michael J.

The polyketide natural product (+)-SCH 351448, a macrodiolide ionophore bearing 14 stereogenic centers, is prepared in 14 steps (LLS). In eight prior syntheses, 22-32 steps were required. Multiple chemoselective and redox-economic functional group interconversions collectively contribute to a step-change in efficiency.

2011-09-02·Organic Letters1区 · 化学

Total Synthesis of (+)-SCH 351448

1区 · 化学

Article

作者: Zhu, Kaicheng ; Panek, James S.

A convergent synthesis of (+)-SCH 351448 (1), a monosodium salt of a C(2)-symmetric macrodiolide, is described. Our approach is based on a [4 + 2] annulation with a chiral allyl silane (anti-5c) to assemble the pyran subunits. Homodimerization was carried out in a stepwise fashion; initial esterification at C29' followed by macrocyclization at C29 afforded the desired macrodiolide.

2011-07-15·Organic Letters1区 · 化学

A Formal Synthesis of SCH 351448

1区 · 化学

Article

作者: Park, Heekwang ; Kim, Hyoungsu ; Hong, Jiyong

An efficient formal synthesis of SCH 351448 was accomplished through the tandem cross-metathesis (CM)/oxa-Michael, the 1,4-syn aldol, the tandem oxidation/oxa-Michael, and the Suzuki coupling reaction.